- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02627833
Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO (FRABO-03)
Lungfunction, Lung Clearance Index, Bronchial Inflammation and Epigenetics of Patients With Bronchiolitis Obliterans
Study Overview
Detailed Description
The purpose of this study is to compare miRNA pattern, lung function values, bronchial inflammation and the Lung clearance index of Patients with Bronchiolitis obliterans aged between 6 up to 30 years of age with a matched control group.
The sputum samples will be processed and quantitatively analyzed to get a profile of the cytological composition.
Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and by cytometric bead assay (CBA). miRNA samples will be collected, processand compared with the miRNA database at http://www.mirbase.org/
Methods and Work Programme:
- Measurement of nitric oxide in expired air (FeNO)
- Lung function testing with spirometry and body plethysmography
- Lung clearance index (LCI)
- Bronchodilation
- Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of the non-specific pulmonary defense system), miRNA analysis
- Induced sputum for inflammatory mediators and microbiological investigations
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Martin Rosewich, MD
- Phone Number: 5381 +49-69-6301
- Email: Martin.rosewich@kgu.de
Study Locations
-
-
Hessen
-
Frankfurt am Main, Hessen, Germany, 60590
- Recruiting
- Children's Hospital, Goethe-University
-
Contact:
- Martin Rosewich, MD
- Phone Number: 5381 49-69-6301
- Email: Martin.Rosewich@kgu.de
-
Contact:
- Stefan Zielen, MD, PhD
- Phone Number: 83063 49-69-6301
- Email: Stefan.Zielen@kgu.de
-
Principal Investigator:
- Martin Rosewich, MD
-
Sub-Investigator:
- Stefan Zielen, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- informed consent
- age between 6 an 35 years
- known bronchiolitis obliterans (Group Bronchiolitis)/ no Bronchiolitis Obliterans (Group matched controls)
- ability to perform lung function tests and inhale correctly
Exclusion Criteria:
- <6 years of age
- >35 years of age
- acute systemic or bronchial inflammation
- other chronic diseases or infection (e.g. HIV, Tbc, malignoma)
- pregnancy
- alcohol, drug or illegal drug abuse
- disability to register the range and consequences of the study
- actual participation in another study
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subject Group
Patients suffering from Bronchiolitis Obliterans
|
Record lung function, Lung clearance index, inflammatory status
|
Control Group
Age and sex matched control group
|
Record lung function, Lung clearance index, inflammatory status
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
miRNA Status
Time Frame: single day observation
|
Blood sample to determine candidate miRNA for Bronchiolitis obliterans
|
single day observation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lung clearance index (LCI)
Time Frame: single day observation
|
Determine Lung clearance index with the Oxygen washout method
|
single day observation
|
FVC [%-pred.]
Time Frame: single day observation
|
Compare FVC [%-pred.] of BO Patients with a healthy control group
|
single day observation
|
FEV1 [%-pred.]
Time Frame: single day observation
|
Compare FEV1[%-pred.] of BO Patients with a healthy control group
|
single day observation
|
Tiffeneau Index
Time Frame: single day observation
|
Compare Tiffeneau-Index of BO Patients with a healthy control group
|
single day observation
|
sRtot [%-pred.]
Time Frame: single day observation
|
Compare sRtot[%-pred.] of BO Patients with a healthy control group
|
single day observation
|
RV/TLC [%-pred.]
Time Frame: single day observation
|
Compare RV/TLC[%-pred.] of BO Patients with a healthy control group
|
single day observation
|
DLCO [%-pred.]
Time Frame: single day observation
|
Compare difffusion capacity of the lung for CO [%-pred.] of BO Patients with a healthy control group
|
single day observation
|
IL-6 (pg/ml)
Time Frame: single day observation
|
Comparing IL-6 in Serum of patients with BO with a healthy control group
|
single day observation
|
IL-8 (pg/ml
Time Frame: single day observation
|
Comparing IL-8 in Serum of patients with BO with a healthy control group
|
single day observation
|
Il-17 (pg/ml)
Time Frame: single day observation
|
Comparing IL-17 in Serum of patients with BO with a healthy control group
|
single day observation
|
CrP (mg/dl)
Time Frame: single day observation
|
Comparing CrP in Serum of patients with BO with a healthy control group
|
single day observation
|
FeNO ppb
Time Frame: single day observation
|
Comparing FeNO in exhaled air of patients with BO with a healthy control group
|
single day observation
|
Sputum cell count
Time Frame: single day observation
|
Comparing sputum cell counts of patients with BO with a healthy control group
|
single day observation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Martin Rosewich, MD, Johann Wolfgang Goethe University Hospital
Publications and helpful links
General Publications
- Kurland G, Michelson P. Bronchiolitis obliterans in children. Pediatr Pulmonol. 2005 Mar;39(3):193-208. doi: 10.1002/ppul.20145.
- Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest. 1998 Nov;114(5):1411-26. doi: 10.1378/chest.114.5.1411. No abstract available.
- Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children. Curr Opin Pediatr. 2008 Jun;20(3):272-8. doi: 10.1097/MOP.0b013e3282ff62e9.
- Pichler M, Herrmann G, Schmidt H, Ahrens P, Zielen S. Persistent adenoviral infection and chronic obstructive bronchitis in children: is there a link? Pediatr Pulmonol. 2001 Nov;32(5):367-71. doi: 10.1002/ppul.1145.
- Rosewich M, Zissler UM, Kheiri T, Voss S, Eickmeier O, Schulze J, Herrmann E, Ducker RP, Schubert R, Zielen S. Airway inflammation in children and adolescents with bronchiolitis obliterans. Cytokine. 2015 May;73(1):156-62. doi: 10.1016/j.cyto.2014.10.026. Epub 2015 Mar 6.
- Motameny S, Wolters S, Nurnberg P, Schumacher B. Next Generation Sequencing of miRNAs - Strategies, Resources and Methods. Genes (Basel). 2010 Jun 3;1(1):70-84. doi: 10.3390/genes1010070.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRosewich
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis Obliterans
-
University Hospital, Basel, SwitzerlandRecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)Switzerland, Saudi Arabia
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; Mallinckrodt; Centers for Medicare...Active, not recruitingBronchiolitis Obliterans Syndrome (BOS)United States
-
Renovion, Inc.RecruitingPre-Bronchiolitis Obliterans SyndromeUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
University of ChicagoCompletedBronchiolitis Obliterans SyndromeUnited States
-
Zambon SpATerminatedStem Cell Transplant Complications | GVHD, Chronic | Bronchiolitis Obliterans Syndrome (BOS)Spain, France, Germany
-
University Hospital RegensburgClinAssess GmbHUnknownSteroid-refractory Bronchiolitis ObliteransGermany
-
KU LeuvenUniversity Hospital, Gasthuisberg; Fund for Scientific Research, Flanders,...CompletedGraft Rejection | Respiratory Infection | Bronchiolitis Obliterans Syndrome | Lymphocytic BronchiolitisBelgium
-
Hopital FochCompletedBronchiolitis Obliterans SyndromeFrance
-
Zambon SpAEnrolling by invitationBronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative BronchiolitisFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
Clinical Trials on observation
-
University of MichiganKuwait Foundation for the Advancement of SciencesCompletedGingival RecessionUnited States
-
Centre Hospitalier Régional d'OrléansCompleted
-
Istanbul University - Cerrahpasa (IUC)CompletedBrachial Plexus Palsy | Obstetric; InjuryTurkey
-
Istanbul Medeniyet UniversityIstinye University; Ufuk UniversityRecruiting
-
Abant Izzet Baysal UniversityRecruitingMultiple SclerosisTurkey
-
Universidad Autonoma de MadridCompleted
-
Universidad Autonoma de MadridUnknown
-
University of BergenEuropean Society of Intensive Care MedicineCompletedCritical Illness | Old Age; Debility | SurvivalNorway
-
IRCCS San Camillo, Venezia, ItalyUniversità Politecnica delle Marche; University of GenovaUnknown
-
Dokuz Eylul UniversityIzmir Katip Celebi UniversityCompleted